Life Sciences Archive » September, 2024

Life Sciences - September, 2024

250 articles

• Takeda End Payors, Direct Buyers Win Antitrust Class Cert.
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• Consumer 'Overslept' On Some Drowsy Cough Syrup Claims
• Bristol-Myers Beats Celgene Investors' Drug Delay Suit
• J&J Backs Off 340B Rebate Plan Following Feds' Objections
• Generic-Drug Co. Says To Think Again About 'Double Patenting'
• Allergan Ruling Reinforces Value Of Patent Term Adjustments
• FTC Focus: How Scrutiny Of PBMs And Insulin May Play Out
• Medical Device Co. Wins $25M Verdict In Poaching Trial
• AI May Limit Key Learning Opportunities For Young Attorneys
• J&J Exec Accused Of File Heist Wants Pause Amid DOJ Case
• Kappos' Bayh-Dole Warning To Clients Draws Debate
• 9th Circ. Says Stem Cell Treatment Not Exempt From FDA Rule
• Why Many Drugs Remain Pricey 40 Years After Hatch-Waxman
• Pharma Co. Amarin Beats Class Action Over Patent Issues
• Life Sciences Firms Energize IPO Market As Recovery Builds
• Advil Owner Haleon Paying $637M To Up Stake In China JV
• Medical Equipment Co., Founder Settle FCA Suit For $20M
• SEC Fines Cassava $40M Over Alzheimer's Treatment Claims
• 11th Circ. Affirms Convictions In Fla. Shark Rescue Case
• 2nd Circ. Denies Jury Trial In Abbott Labs Gray Market Case
• New Report Urges Feds To Take Larger Role In Pot Policy
• Walgreens Struggles To Exit 'Non-Drowsy' Label Suit In Wash.
• NC Medical Equipment Maker Can't Ditch Unfair Biz Suit
• Obesity Drug Developer Leads 2 Upsized IPOs Totaling $310M
• Virtua Discriminates Against Pregnant Patients, NJ Alleges
• Senate Patent Bill Markups Delayed Until After Election
• Nobel Winners Behind Gene Editor Seek To Nix Own Patents
• Quest Diagnostics Escapes 401(k) Mismanagement Suit
• In-House Counsel To Play Central Role At AI Cos., VCs Say
• NY Judge Pauses Abortion 'Reversal' Case As AG Files Appeal
• Ascension Must Face Additional Suit Over Vaccine Mandate
• Generics Group Names Ex-BIO, PhRMA Exec As New CEO
• 3rd Circ. Preserves Monsanto's Win In Cancer Warning Suit
• 7th Circ. Judge Surprised Key Argument Left In Footnote
• NJ Pharmacy Execs Cop To $33M Kickback Scheme
• Wyden Pitches New Bill To Regulate Intoxicating Hemp
• DC Circ. Judges Ask If It's Too Late To Fast-Track Gastro Drug
• Expect More R&D Guidance Before Regs, IRS Atty Says
• Cancer Detection Biz To Go Public Via $694M SPAC Merger
• AmerisourceBergen Can't Escape Workers' 401(k) Fee Suit
• Round-Canopy Parachuting Makes Me A Better Lawyer
• And Now A Word From The Panel: The MDL Map
• Google Can't Ditch Privacy Suit Over Period App Data Sharing
• Biotech RenovaCare Investors Seek OK Of $2M Deal
• P&G Says FDA Review Moots Class Suit Over Lead In Tampons
• Philips Must Face Investor Suit Over FDA Compliance Issues
• Buyers Seek $97M Fees From $335M Drug Price-Fixing Deals
• Novo Nordisk Tells Sens. Ozempic Costs Are Linked To PBMs
• Trio Used Penny Stock Co. For Wide-Ranging Fraud, SEC Says
• Moderna Execs Hyped Ineffective RSV Vax, Suit Says
• Navigating Restrictions Following Biotech Bill House Passage
• Firms Allowed To Exit IP Case After Gaining Philips' Consent
• 8th Circ. Won't Revive Pot Shop's Discrimination Suit
• NJ Judge Leaves J&J Ch. 11 Venue Change To Texas Judge
• Why Now Is The Time For Law Firms To Hire Lateral Partners
• J&J Talc Claims Paused In Latest Spinoff Ch. 11
• Mallinckrodt Brass Can't Avoid Investor Suit Over 2nd Ch. 11
• Bio Lab Settles Conn. False-Claims Allegations For $1.73M
• Fired Sotera Exec's Vesting Suit Goes Forward In Del.
• GSK Claims Pfizer Hasn't Proven Misconduct In Vax IP Fight
• Fed. Circ. OKs Novartis Loss In Eye Syringe Patent Feud
• Amneal Latest Generic EpiPen Maker To Fight Colo. Law
• Cancer Test Cos. Strike Deal For Partial End To Patent Row
• A Look At The Economic Impact Of Drug Patent Differentiation
• Insurer Freed From Damaged Blood Plasma Suit
• J&J Accuses Beasley Allen Of Casting Bogus Talc Ballots
• Considering Possible PR Risks Of Certain Legal Tactics
• RSV Vaccine Biz Secures $100M For Series B Funding Round
• Kratom Co. Gets Claims Trimmed In Addiction False Ad Row
• House To Weigh Patent Bill Aimed At Cutting Drug Prices
• ITC Has Been Launching Fewer Section 337 Investigations
• Alnylam Seeks To End Inventorship Suit Tied To COVID Vax
• 3rd Circ. Rejects 'Close' Case For Preemption In Fosamax MDL
• Del. Justices Uphold Toss Of AmerisourceBergen Syringe Suit
• IPO Trio Looks To Raise $536M Combined As Autumn Begins
• DuPont Cos. Can't Escape Cape Fear River PFAS Suit
• Lawmakers Ask USPTO To Fix Patent Calculation Problem
• Plaintiffs Firms Battle Over Proposed $9B Deal In J&J Talc Suit
• Ex-Healthcare Exec Can't Sue GC Over Probe Advice
• J&J Makes Third Try At Handling Talc Claims In Bankruptcy
• It's No Longer Enough For Firms To Be Trusted Advisers
• Cardinal Health Pays $1.12B For Integrated Oncology Network
• Womble Bond Hires New Head Of Int'l Disputes From Dechert
• Ga. Airport Pat-Down Caused Catastrophic Injuries, Man Says
• UK Litigation Roundup: Here's What You Missed In London
• FTC Accuses Drug Middlemen Of Raising Insulin Prices
• Bills On Patent Eligibility, PTAB Limits Near Senate Markup
• AndroGel Antitrust Case On Hold Amid Settlement Talk
• Ga. Appeals Court Says Hospital Must Get Certificate Of Need
• Another Ill. Jury Deadlocks Over Zantac Cancer Claims
• Convicted Drexel Professor Won't Get New Tax Evasion Trial
• Norwich Asks Justices To Allow Sale Of Generic Diarrhea Drug
• Vertex Suit Highlights Issues For Pharma Fertility Support
• Conn. Justices Wonder How 'Malicious' Firm's Ex-Client Was
• Airline Sinks Bias Suit From Worker Fired Over Drug Test
• Axonics Didn't Infringe Medtronic Patents, Calif. Jury Says
• CVS Unit Pays $60M Over Alleged Insurance Kickback Scheme
• 7th Circ. Questions Nixing $183M Eli Lilly Drug Rebate Verdict
• Fed. Circ. Revives Astellas Patent Axed As Natural Law
• Rescheduling Pot Would Not Hasten Research, Report Says
• Georgia High Court Won't Hear Missed Patent Deadline Case
• SEC Settles Latest Covington Info Theft Case For $33K
• Ex-Amgen Rep Wasn't Original Whistleblower, Judge Says
• ITC Looking At Advanced Bionics Implant Patent Claims
• Thermo Fisher Late To Pay Departing Workers, Engineer Says
• GSK Inks 2 Calif. Zantac Deals
• Biotech Co. Escapes Stock-Drop Suit Over COVID-19 Drug
• Organon To Buy Psoriasis Treatment Biz For Up To $1.2B
• Benefit Funds Sue Sandoz Over Alleged Fraudulent Transfers
• CMS' New 'Breakthrough' Device Policy Shows Little Promise
• GC Base Salaries At Big Companies On The Rise
• Philip Morris To Part With Inhaler Maker In Up To £258M Deal
• Express Scripts Blasts 'Biased' FTC Drug Middlemen Report
• Merit Medical To Buy Rival's Heart Implant Biz For $210M
• Teleflex Gets Another Chance In Catheter Patent Feud
• Injectable Analgesic Maker Wants Generic Version Blocked
• Pot Co. Execs Go To 9th Circ. In Investment Scam Case
• 5th Circ. Judge Chides High Court Calls in Abortion Pill Case
• Pall Corp. Shorts Workers By Rounding OT, Suit Says
• J&J Cheers Toss Of 'Indefensible' $260M Talc Verdict
• Bayer Beats IP Firm's Bid To Nix European MRI Patent
• Nebraska Medical Cannabis Initiatives Will Be On Nov. Ballot
• NHS To Pay £87K To Clinician Who Quit Due To Low Funding
• McCarter & English's Misstatement Won't Nix Malpractice Win
• The 2024 Regional Powerhouses
• Sandoz Awarded $137M In Generic Hypertension Drug Fight
• Walgreens To Pay $107M To End 3 False Billing Claims Suits
• Judge Orders Mobile IV Co. To Stop Eli Lilly Infringment
• EU Actors Lobby Hard For Top Jobs in New Commission
• Kennedys Hires Cyber, AI Pro From Addleshaw In London
• New Lessons On Managing Earnout Provision Risks
• 3 Patent Considerations For America's New Quantum Hub
• SEC Fines Zymergen $30M Over Misleading Pre-IPO Claims
• Trio Of BigLaw Mergers Expected To Drive More Deal Talks
• Emergent BioSolutions Pays $40M To Settle COVID Vax Suit
• Med Techs Settle Eyelid Cleaner Patent Spat
• 2 Life Sciences Cos. Start Trading After Raising $540M Total
• Makers Of Paragard Say Time Ran Out On Claims In 236 Suits
• Ex-DOJ Deputy In TikTok, Twitter Cases Joins Mayer Brown
• UK Litigation Roundup: Here's What You Missed In London
• NHS Scotland Sues Accord, Allergan Over Drug Pricing
• Former MilliporeSigma Patent Atty Joins Polsinelli In St. Louis
• Ropes & Gray Helps Kohlberg Net $4.3B For 10th PE Fund
• French Vaccine Maker Valneva Raises €61M In Private Placing
• Alcon Loses European Patent Over Eye Imaging Tech
• A Preview Of AI Priorities Under The Next President
• Wilson Sonsini Hires Tax Pro From Slaughter and May
• Faegre Drinker Adds White Collar Trio From Greenberg Traurig
• Mass Tort Boutique Leader On Sizing Up With Anapol Weiss
• Greenberg Traurig Grows Health Team With Ex-NY Official
• Stites & Harbison Eyes Conn. Office With Patent Team Pickup
• Sullivan & Cromwell Guides Springer Nature's German IPO
• Sanofi Sets €320M Licensing Deal With US, French Biotechs
• Danish Pharma Co. Is Entitled To VAT Reduction
• Litigation Spending To Rise As Cases Grow More Aggressive
• Gender Care Hearing Centers On Ohio Bill Of Rights
• Gov't Spent $236B In Fraud And Improper Payments In 2023
• Top Calif. Biz Bills Sitting On Gov. Newsom's Desk
• How Companies Are Approaching Insider Trading Policies
• 11 Patent Cases To Watch At Fed. Circ. And High Court
• Indivior, Reckitt Benckiser Units Freed From Suboxone MDL
• King & Spalding Adds 4 Attys To Mass Torts Practice In Texas
• Ipsen Exec Made Illegal Trades Before Merger, Feds Say
• Proskauer Lands Fried Frank's Arbitration Head In London
• Phelps Dunbar Recruits 6 Litigators In Raleigh
• Trademarks Surge As UKIPO Transforms Digital Platform
• IP Boutique Hires Murgitroyd Pro For Life Sciences Team
• Dentons Adds 2 Corp. Pros In Dublin From US Rivals
• Sandoz Can't Patent Generic Hypertension Drug
• SEC Files New Insider Case Tied To Stolen Covington Info
• 3rd. Circ. Got It Right On Cancer Warning Claims Preemption
• Neb. Midwife Can't Sue For 'Hypothetical' Clients, Judge Rules
• Cybersecurity Co. Beats Suit Over Med Tech Data Breach
• House Reps. Float Bill To Limit Patent Invalidations
• Philips Balks At Dentons' Request To Exit IP Case
• Free Speech Or Bad Medicine? The Abortion 'Reversal' Battle
• Swedish Biopharma Vicore Announces Plans To Raise $75M
• Cooley Hires Team For Emerging Companies And VC Practice
• Ex-Outcome CEO Says Issues Warrant Bond Pending Appeal
• Pa. Supreme Court Snapshot: Benefits, Cannabis, Taxes
• Exec Denied New Trial In 'Shadow Trading' Case, Fined $321K
• Insurer Needn't Cover Lab Fraud Suits, Ill. Judge Rules
• Ex-Finance Exec To Pay SEC $110K In Insider Trading Action
• Purdue Sees Another OxyContin Patent Axed
• Abbott Says Illinois OT Suit Should Join Similar Case In Ohio
• House OKs Bill To Bar Contracts With Chinese Biotech Cos.
• FTC Backs Teva Orange Book Delisting At Fed. Circ.
• Biotech Execs Face Investor Suit Over Medicare Claims
• Generics Makers Want Mo. Sanctioned In Price-Fixing Case
• To Lower Drug Prices, Harris Must Address Patent Thickets
• MBX Biosciences Seeks Up To $136M In Upcoming IPO
• Baltimore Strikes $80M Opioid Settlement With Teva
• Novo Nordisk Sues Over Ads For Diabetes, Weight Loss Drugs
• Novartis Settles Sales Rep.'s Gender Bias Suit
• How Methods Are Evolving In Textualist Interpretations
• Catching Up With Delaware's Chancery Court
• 2nd Circ. Upholds Regeneron's Win In Remote Work Suit
• Ore. Seeks Dismissal Of Psilocybin Disabilities Suit
• AstraZeneca Unit Owes $130M In Chancery Scuttled-Drug Suit
• Actelion Must Face Tracleer Antitrust Suit With Class Certified
• Biopharm Co., Directors Sued In Del. Over 'Extreme' Scheme
• NJ Medical Co. Claims Ex-Employees Conspired To Form Rival
• Ingersoll Rand Blocks Rival From Hiring Ex-Exec In NDA Fight
• Travel Nurse Says Emory Ended Her Contract Over Race Bias
• Goodwin-Led Cancer Biotech Eyes Roughly $200M IPO
• Glioblastoma Org. Wants End To Rival's Use Of 'GBM'
• Trending At The PTAB: Obviousness In Director Reviews
• Lawmakers, AGs Urge Justices To OK Denial Of E-Cig Apps
• Law Firms Appeal Atty Fee Denial In Opioid Settlements
• Class Attys Vie To Lead Drug Co. Insider Trading Suit In Del.
• Lupin Infringes Exeltis Contraceptive Patents, Judge Finds
• Pharma Co. Verrica Fails To Shed Investor Suit Over FDA OK
• Why Attorneys Should Consider Community Leadership Roles
• Albertsons Denied Texas Court Remand In Opioid MDL
• Leech Tishman Combines With Calif. Firm Nelson Hardiman
• Medical Cos. Must Provide Doctor Names In Fla. Qui Tam Suit
• Bid To Nix Expert Fails As Fed. Circ. OKs $2.3M Patent Verdict
• Ga. Justices Won't Disturb Distributors' Opioid Trial Win
• Groups Urge DC Circ. To Reject Pharma Terrorism Liability Claims
• Zoetis Sanctions Bid Denied In Racehorse Death Suit
• Whittaker Seeks $535M Deal In Talc Cases Tied To Berkshire
• NC Biz Court Bulletin: Blackbeard IP Fight, Firm Data Breach
• Chamber Backs Gilead's Immunity In COVID Appeal
• Agencies Should Reward Corporate Cyber Victim Cooperation
• Glenmark Will Pay $25M To End Feds' Price-Fixing Suit
• McCarter & English Rips Challenge To Malpractice Win In NJ
• Trade Group Urges Court To Toss FDA Lab-Test Rule
• Ga. Justices Affirm Rejection Of Class In Patient Privacy Suit
• Firms Must Offer A Trifecta Of Services In Post-Chevron World
• J&J Hit With $1B Damages In Del. Merger Milestone Fight
• Takeaways From UPC's Amgen Patent Invalidity Analysis
• Arnold & Porter Adds Mintz Healthcare Enforcement Leader
• Louisiana Frees Aurobindo, Sandoz From Price-Fixing Suits
• Teva Investors Get Go-Ahead To Resume Kickbacks Class Suit
• Fed. Circ. Mulls PTAB Ruling's Effect On Liquidia Drug Launch
• Monsanto Keeps Trial Win In Missouri Roundup Cancer Suit
• HQ Specialty Looks To Fix Patent Flaws After Delaware Trial
• Teva Patents Don't Belong In Orange Book, Fed. Circ. Told
• Aesthetic Laser Co. Tells Jury Of Rival's 'Corporate Raid'
• 3rd Circ.: Biotech Must Pay Royalties Despite Expired Patents
• 5 Ways Life Sciences Cos. Can Manage Insider Trading Risk
• Gov't Backs 9th Circ. Bid To Revive Invisalign Monopoly Case
• Aspire Biopharma Inks SPAC Deal At $316M Valuation
• Catching Up With Delaware's Chancery Court
• Scientist Says Yale Medical School Ruined $28M 'Life's Work'
• 5 Tips To Succeed In A Master Of Laws Program And Beyond
• Glenmark Hit With $50M Suit Over Potassium Pill Death
• Semnur Pharmaceuticals To Go Public Via $2.5B SPAC Merger
• Hogan Lovells Tech Transactions Ace Returns To Weil In SF